# Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Source: https://onco.cc/trials/nct04262466/  
OnCo record `nct04262466` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Brenetafusp, Pembrolizumab, Tebentafusp and Bevacizumab in advanced solid tumours, run by Immunocore Ltd, active and no longer recruiting.

## Summary

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors is a phase 1/2 interventional study registered as NCT04262466 by Immunocore Ltd, with 410 participants enrolled, started 2020-02-25 and due to reach its primary completion in 2026-10. Interventions recorded: Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp and Brenetafusp and bevacizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04262466
- Phase: 1/2
- Setting: Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
- Sponsor: Immunocore Ltd
- Enrolled: 410

## Sources

- ClinicalTrials.gov NCT04262466: https://clinicaltrials.gov/study/NCT04262466

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Brenetafusp](https://onco.cc/drugs/brenetafusp/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Tebentafusp](https://onco.cc/drugs/tebentafusp/)
- companies: [Immunocore](https://onco.cc/companies/immunocore/)

---
JSON: https://onco.cc/api/v1/entities/nct04262466.json